SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-19-043525
Filing Date
2019-11-14
Accepted
2019-11-14 16:17:13
Documents
66
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q trvi-10q_20190930.htm 10-Q 2715403
2 EX-31.1 trvi-ex311_9.htm EX-31.1 14075
3 EX-31.2 trvi-ex312_8.htm EX-31.2 13926
4 EX-32.1 trvi-ex321_7.htm EX-32.1 8655
5 EX-32.2 trvi-ex322_6.htm EX-32.2 8762
  Complete submission text file 0001564590-19-043525.txt   7832337

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT trvi-20190930.xml EX-101.INS 1407414
7 XBRL TAXONOMY EXTENSION SCHEMA trvi-20190930.xsd EX-101.SCH 61617
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE trvi-20190930_cal.xml EX-101.CAL 44728
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE trvi-20190930_def.xml EX-101.DEF 193010
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE trvi-20190930_lab.xml EX-101.LAB 430186
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE trvi-20190930_pre.xml EX-101.PRE 333527
Mailing Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

IRS No.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38886 | Film No.: 191220437
SIC: 2834 Pharmaceutical Preparations